USA-based drug developer Alder BioPharmaceuticals (Nasdaq: ALDR) has lost a quarter of its share price after announcing Phase III results from a trial of migraine candidate eptinezumab.
While the trial achieved its primary endpoint and key secondary endpoints, investors were likely disappointed by efficacy data which showed only a slight improvement over placebo.
In a highly competitive market for new migraine treatments, Alder’s investigational biologic, which is administered quarterly via infusion, is up against Amgen’s (Nasdaq: AMGN) erenumab, Eli Lilly’s (NYSE: LLY) galcanezumab and Teva Pharmaceutical’s (NYSE: TEVA) fremanezumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze